Physician profile
Saied T Murphy
NPI 1205894631
$7,490.67
in general payments reported to CMS, 2019-2025
11 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $174 · 2021: $111 · 2022: $244 · 2023: $437 · 2024: $5,881 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,025 · Food and Beverage: $1,193 · Travel and Lodging: $1,171 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,025.00 |
| Food and Beverage | $1,192.57 |
| Travel and Lodging | $1,170.95 |
| Education | $173.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,851.00 | 2019-2025 | Krystexxa |
| Horizon Therapeutics Plc | $619.36 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $414.40 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $225.80 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $109.39 | 2020-2024 | Acthar |
| Abbvie INC. | $97.94 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $88.57 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.91 | 2025 | Lokelma |
| Calliditas Therapeutics US INC. | $24.14 | 2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $18.50 | 2021 | |
| Akebia Therapeutics INC | $16.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saied Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.